Download PDF
Thromb Haemost 2000; 84(04): 730-731
DOI: 10.1055/s-0037-1614099
Letters to the Editor
Schattauer GmbH

C-reactive Protein, Idiopathic Venous Thromboembolism and Hormone Replacement Therapy

Gordon Lowe
1   From the University Department of Medicine, Royal Infirmary, Glasgow
,
Ann Rumley
1   From the University Department of Medicine, Royal Infirmary, Glasgow
,
Mark Woodward
2   Department of Applied Statistics, University of Reading, University of Oxford, UK
,
Martin Vessey
3   Department of Public Health, University of Oxford, UK
› Author Affiliations
Further Information

Publication History

Received 26 June 2000

Accepted 29 June 2000

Publication Date:
11 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Kamphuisen PW, Eikenboom JCJ, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Ridker PM, Cushman M, Stampfer MJ, Tracy RM, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
    CrossrefPubMedSearch in Google Scholar
  • 3 Ridker PM, Buring JE, Shin J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
    CrossrefPubMedSearch in Google Scholar
  • 4 Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
    PubMedSearch in Google Scholar
  • 5 Rumley A, Lowe GDO, Upton MN, McConnachie A, O’Reilly DSJ, Watt GCM. Associations of menopause and different hormone replacement therapies with thrombotic variables and C-reactive protein. Blood Coagul Fi-brinolys 1999; 10 Suppl: 36.
    PubMedSearch in Google Scholar
  • 6 van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis JJ, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-8.
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893-9.
    CrossrefPubMedSearch in Google Scholar
  • 8 Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
    CrossrefPubMedSearch in Google Scholar
  • 9 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998; 280: 605-13.
    CrossrefPubMedSearch in Google Scholar
  • 10 Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-5.
    Thieme ConnectPubMedSearch in Google Scholar